TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Revenue of TScan Therapeutics, Inc. (TCRX)
Revenue in 2023 (TTM): $21.05 M
According to TScan Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $21.05 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of TScan Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $21.05 M | $-67,104,000 | $-80,098,000 | $-89,218,000 | $-89,218,000 |
| 2022 | $13.54 M | $8.4 M | $-59,907,999 | $-66,221,000 | $-65,806,000 |
| 2021 | $10.14 M | $6.81 M | $-45,297,000 | $-48,625,000 | $-48,625,000 |
| 2020 | $1.09 M | $-19,492,000 | $-25,003,000 | $-26,127,000 | $-26,021,000 |
| 2019 | $ | $-519,000 | $-13,691,000 | $-13,658,000 | $-13,106,000 |